Transplantation is a life-saving procedure for many patients with organ failure, but significant challenges remain. In particular, Innobiochips' SirYus technology addresses the hurdles associated with prediction and monitoring of organ compatibility.

Even with a successful transplant, the body's immune system may recognize the transplanted organ as foreign and attack it. Matching a donor organ to a recipient is critical to successful transplantation. While significant progress has been made, there's still room for improvement in predicting compatibility and reducing the risk of rejection.

Innobiochips has developed an in vitro diagnostic technology for the identification of anti-HLA antibodies on a multiplex immunodiagnostic basis and provides high resolution antibody identification results to predict compatibility and avoid acute rejection. This solution enables the automation of a partially manual process and provides more reliable and accurate biological data.


Syrius logo
A new breakthrough technology to predict and monitor organ compatibility for transplantation

SirYus is based on a broad family of patented functionalization agents (WO2012/052874) and a novel surface chemistry approach that enables the printing, immobilization and stabilization of various biomolecules (e.g. peptides, antibodies, polysaccharides...).

The SirYus technology is now produced and distributed by BAG Diagnostics, a major player in the diagnostics market. Innobiochips took care of all industrialization activities: prototyping, small-scale production and support in the transition to mass production.

More about the SirYus-based transplantation diagnostic solution on the BAG Diagnostics site